Endometrial Cancer

Oncology
24
Pipeline Programs
24
Companies
50
Clinical Trials
5 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
14
0
6
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
444%
Monoclonal Antibody
222%
Small Molecule
222%
Peptide
111%
+ 18 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
HYCAMTINApproved
topotecan
Novartis
oral2007

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
1
1
BEZ235Phase 21 trial
HYCAMTIN(Topotecan)Phase 13 trials
Active Trials
NCT01417806Unknown28Est. Dec 2016
NCT00703807Completed10Est. May 2010
NCT00960739Completed30Est. Jul 2016
+1 more trials
DS
Daiichi SankyoChina - Shanghai
3 programs
1
2
Trastuzumab DeruxtecanPhase 3ADC1 trial
Trastuzumab deruxtecanPhase 3ADC1 trial
Datopotamab deruxtecanPhase 2ADC1 trial
Active Trials
NCT05489211Recruiting582Est. Aug 2026
NCT07022483Recruiting710Est. Mar 2032
NCT06989112Recruiting600Est. Feb 2031
Karyopharm Therapeutics
2 programs
2
SelinexorPhase 31 trial
SelinexorPhase 31 trial
Active Trials
NCT03555422Active Not RecruitingEst. Dec 2025
NCT05611931RecruitingEst. Jan 2028
CT
1 program
1
Anlotinib hydrochloride capsule + TQB2450 injectionPhase 31 trial
Active Trials
NCT06475599Not Yet RecruitingEst. Jun 2029
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
Sacituzumab govitecan-hziyPhase 3ADC1 trial
Active Trials
NCT06486441Active Not Recruiting640Est. Jun 2029
Ipsen
IpsenChina - Tianjin
2 programs
2
BN83495Phase 21 trial
BN83495Phase 21 trial
Active Trials
NCT01251354Terminated6Est. Jul 2011
NCT00910091Completed73Est. Jul 2013
Sanofi
SanofiPARIS, France
2 programs
2
XL147Phase 25 trials
aminopterinPhase 21 trial
Active Trials
NCT01357330Completed18Est. Jun 2012
NCT01240460Completed40Est. Jun 2012
NCT01082068Completed72Est. Apr 2013
+3 more trials
Genentech
GenentechCA - Oceanside
1 program
1
BevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03526432Active Not Recruiting110Est. Sep 2026
Bayer
BayerLEVERKUSEN, Germany
1 program
1
CopanlisibPhase 2Small Molecule5 trials
Active Trials
NCT06238583No Longer Available
NCT05082025Terminated7Est. Dec 2025
NCT04750941Terminated1Est. Jun 2023
+2 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
GiredestrantPhase 21 trial
Active Trials
NCT05634499Active Not Recruiting30Est. Jun 2026
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT01111461Completed133Est. Oct 2015
B
ByondisNetherlands - Nijmegen
1 program
1
SYD985Phase 21 trial
Active Trials
NCT04205630CompletedEst. Apr 2023
Xenetic Biosciences
Xenetic BiosciencesFRAMINGHAM, MA
1 program
1
Sodium CridanimodPhase 21 trial
Active Trials
NCT03077698TerminatedEst. Jul 2020
Zymeworks
ZymeworksMIDDLETOWN, DE
1 program
1
ZW25Phase 21 trial
Active Trials
NCT04513665CompletedEst. Mar 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
arzoxifene hydrochloridePhase 22 trials
Active Trials
NCT00003669CompletedEst. Apr 2001
NCT00003670CompletedEst. Jan 2001
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
AtezolizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05542407Recruiting58Est. Jul 2028
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
IMGN151Phase 11 trial
Active Trials
NCT05527184Active Not Recruiting256Est. Feb 2027
Precision BioSciences
1 program
ChemoFxN/A1 trial
Active Trials
NCT01049126Completed76Est. Feb 2010
Verona Pharma
Verona PharmaUK - London
1 program
HysteroscopyN/A1 trial
Active Trials
NCT05717634UnknownEst. Jan 2024
Accuray
AccurayMADISON, WI
1 program
Stereotactic Post-operative Radiotherapy for Endometrial CancerN/A1 trial
Active Trials
NCT06360653Recruiting60Est. May 2027
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
semaglutideN/APeptide1 trial
Active Trials
NCT07462663Not Yet Recruiting82Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Daiichi SankyoTrastuzumab Deruxtecan
Daiichi SankyoTrastuzumab deruxtecan
Gilead SciencesSacituzumab govitecan-hziy
Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule + TQB2450 injection
Karyopharm TherapeuticsSelinexor
Karyopharm TherapeuticsSelinexor
BayerCopanlisib
BayerCopanlisib
RocheGiredestrant
BayerCopanlisib
Daiichi SankyoDatopotamab deruxtecan
BayerCopanlisib
BayerCopanlisib
BayerCopanlisib
ZymeworksZW25

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 4,611 patients across 50 trials

NCT07022483Daiichi SankyoTrastuzumab Deruxtecan

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Start: Sep 2025Est. completion: Mar 2032710 patients
Phase 3Recruiting
NCT06989112Daiichi SankyoTrastuzumab deruxtecan

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Start: Mar 2025Est. completion: Feb 2031600 patients
Phase 3Recruiting
NCT06486441Gilead SciencesSacituzumab govitecan-hziy

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Start: Aug 2024Est. completion: Jun 2029640 patients
Phase 3Active Not Recruiting
NCT06475599Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule + TQB2450 injection

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Start: Jul 2024Est. completion: Jun 2029
Phase 3Not Yet Recruiting
NCT05611931Karyopharm TherapeuticsSelinexor

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Start: Apr 2023Est. completion: Jan 2028
Phase 3Recruiting
NCT03555422Karyopharm TherapeuticsSelinexor

Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]

Start: Jan 2018Est. completion: Dec 2025
Phase 3Active Not Recruiting
NCT02369016BayerCopanlisib

Phase III Copanlisib in Rituximab-refractory iNHL

Start: Sep 2015Est. completion: Oct 202225 patients
Phase 3Completed
NCT02367040BayerCopanlisib

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Start: Aug 2015Est. completion: Nov 2024458 patients
Phase 3Completed
NCT05634499RocheGiredestrant

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

Start: Jun 2023Est. completion: Jun 202630 patients
Phase 2Active Not Recruiting
NCT05082025BayerCopanlisib

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Start: Sep 2022Est. completion: Dec 20257 patients
Phase 2Terminated
NCT05489211Daiichi SankyoDatopotamab deruxtecan

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Start: Sep 2022Est. completion: Aug 2026582 patients
Phase 2Recruiting
NCT04750941BayerCopanlisib

Study of Copanlisib and Ketogenic Diet

Start: Feb 2022Est. completion: Jun 20231 patients
Phase 2Terminated
NCT04685915BayerCopanlisib

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Start: Feb 2021Est. completion: Mar 20280
Phase 2Withdrawn
NCT05387616BayerCopanlisib

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Start: Oct 2020Est. completion: May 202698 patients
Phase 2Active Not Recruiting
NCT04513665ZymeworksZW25

ZW25 in Women With Endometrial Cancers

Start: Aug 2020Est. completion: Mar 2024
Phase 2Completed
NCT04263584BayerCopanlisib

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Start: Jun 2020Est. completion: Apr 202562 patients
Phase 2Unknown
NCT04205630ByondisSYD985

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Start: May 2020Est. completion: Apr 2023
Phase 2Completed
NCT04155840BayerCopanlisib

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start: Jan 2020Est. completion: Mar 20211 patients
Phase 2Terminated
NCT03474744BayerCopanlisib

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Start: Dec 2019Est. completion: Dec 202736 patients
Phase 2Active Not Recruiting
NCT03526432GenentechBevacizumab

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Start: Aug 2018Est. completion: Sep 2026110 patients
Phase 2Active Not Recruiting
NCT03077698Xenetic BiosciencesSodium Cridanimod

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Start: Jun 2017Est. completion: Jul 2020
Phase 2Terminated
NCT02455297BayerCopanlisib

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Start: Aug 2015Est. completion: Aug 20164 patients
Phase 2Terminated
NCT02391116BayerCopanlisib

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start: May 2015Est. completion: Jan 201867 patients
Phase 2Completed
NCT01660451BayerCopanlisib

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Start: Nov 2012Est. completion: May 2023227 patients
Phase 2Completed
NCT01290406NovartisBEZ235

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Start: Mar 2012Est. completion: Dec 20170
Phase 2Withdrawn
NCT01417806NovartisTopotecan

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

Start: Jul 2011Est. completion: Dec 201628 patients
Phase 2Unknown
NCT01251354IpsenBN83495

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Start: Nov 2010Est. completion: Jul 20116 patients
Phase 2Terminated
NCT01111461EisaiLenvatinib

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Start: Mar 2010Est. completion: Oct 2015133 patients
Phase 2Completed
NCT01013324SanofiXL147

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Start: Jan 2010Est. completion: Mar 201367 patients
Phase 2Completed
NCT00910091IpsenBN83495

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Start: Aug 2009Est. completion: Jul 201373 patients
Phase 2Completed
NCT00960739NovartisTopotecan

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

Start: Nov 2008Est. completion: Jul 201630 patients
Phase 2Completed
NCT00003669Eli Lilly and Companyarzoxifene hydrochloride

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

Start: Nov 1998Est. completion: Apr 2001
Phase 2Completed
NCT00003670Eli Lilly and Companyarzoxifene hydrochloride

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Start: Oct 1998Est. completion: Jan 2001
Phase 2Completed
NCT00003821Sanofiaminopterin

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Start: Jan 19980
Phase 2Withdrawn
NCT04253262BayerCopanlisib

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Start: Apr 2020Est. completion: Jan 202713 patients
Phase 1/2Active Not Recruiting
NCT03877055BayerCopanlisib

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Start: Mar 2019Est. completion: Oct 20228 patients
Phase 1/2Completed
NCT03711058BayerCopanlisib

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Start: Jan 2019Est. completion: Jun 202548 patients
Phase 1/2Completed
NCT03458728BayerCopanlisib

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Start: Apr 2018Est. completion: Feb 202331 patients
Phase 1/2Terminated
NCT01082068SanofiXL147

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Start: Jun 2010Est. completion: Apr 201372 patients
Phase 1/2Completed
NCT01042925SanofiXL147

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Start: Feb 2010Est. completion: Dec 201242 patients
Phase 1/2Completed
NCT05542407Jazz PharmaceuticalsAtezolizumab

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Start: Oct 2023Est. completion: Jul 202858 patients
Phase 1Recruiting
NCT05527184AbbVieIMGN151

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Start: Jan 2023Est. completion: Feb 2027256 patients
Phase 1Active Not Recruiting
NCT04803123BayerCopanlisib

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Start: Jun 2021Est. completion: Apr 20233 patients
Phase 1Terminated
NCT04895579BayerCopanlisib

Lung Cancer With Copanlisib and Durvalumab

Start: May 2021Est. completion: Nov 202511 patients
Phase 1Completed
NCT04431635BayerCopanlisib

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Start: Jun 2020Est. completion: Nov 20236 patients
Phase 1Terminated
NCT03735628BayerCopanlisib

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Start: Oct 2018Est. completion: Oct 202216 patients
Phase 1Completed
NCT03655301BayerCopanlisib

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Start: Sep 2018Est. completion: Feb 201913 patients
Phase 1Completed
NCT03517956BayerCopanlisib

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

Start: Jul 2018Est. completion: Feb 202116 patients
Phase 1Completed
NCT03498430BayerCopanlisib

Copanlisib Chinese PK Study

Start: Apr 2018Est. completion: Jun 202013 patients
Phase 1Completed
NCT03128619BayerCopanlisib

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Start: Aug 2017Est. completion: Mar 202210 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 4,611 patients
24 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)